Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699092 | 0.89 | DRD1 (0.38) | DRD1MEN1KMT2APOLBPABPC1 | |
| SCHEMBL1699084 | 0.89 | DRD1 (0.39) | DRD1MEN1KMT2APOLBPABPC1 | |
| SCHEMBL1699248 | 0.86 | DRD1 (0.38) | DRD1MEN1KMT2APOLBPABPC1 | |
| SCHEMBL14333706 | 0.85 | ALDH1A1 (0.37) | DRD1KMT2APOLBLMNAHDAC1 | |
| SCHEMBL14889112 | 0.85 | DRD1 (0.38) | DRD1MEN1KMT2APOLBPABPC1 | |
| SCHEMBL1699557 | 0.83 | HDAC1 (0.37) | DRD1MEN1KMT2APOLBPABPC1 | |
| SCHEMBL1699111 | 0.83 | PDE10A (0.36) | DRD1MEN1KMT2APOLBPABPC1 | |
| SCHEMBL1699476 | 0.81 | PDE10A (0.36) | DRD1PDE10ALMNAPDE4BHDAC1 | |
| SCHEMBL1699250 | 0.78 | PDE10A (0.36) | DRD1MEN1KMT2APDE10ALMNA | |
| SCHEMBL1699242 | 0.74 | L3MBTL1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512118-B2 | Crystal of fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-06 | — | — | US | disclosed |
| US-20140113932-A1 | CRYSTAL OF FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2585462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012176934-A1 | CRYSTAL OF FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-27 | — | — | WO | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113932-A1 | CRYSTAL OF FUSED HETEROCYCLIC COMPOUND | GRIN2D, GRIN2C, GRIN3A | DRD1 43/4885MEN1 3110/4885KMT2A 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.